Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2018-12-07 Director's Dealing
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
107年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by company insiders, including directors, supervisors, and managers, showing their current holdings, pledged shares, and related information. It includes specific data on share counts and relationships but does not contain financial statements, earnings data, or management discussion. The content is focused on insider shareholdings and their changes, which aligns with reporting on personal share transactions or holdings by company directors and executives. There is no indication of a full financial report, earnings release, or regulatory announcement beyond insider shareholding details. Therefore, the document fits best under the category of Director's Dealing (DIRS). The document length is under 5,000 characters and contains detailed insider shareholding data, not just an announcement or certification, so it is not RNS or RPA. Confidence is high due to the clear insider shareholding focus.
2018-12-07 Chinese
107年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 科妍, providing information about fund lending balances and endorsement guarantees for the current and previous months. It contains tabulated data with no narrative, analysis, or detailed financial statements. The content is very short (601 characters) and does not represent a full financial report or detailed management discussion. It is a regulatory disclosure of specific financial data points, likely a routine compliance filing rather than a comprehensive report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-12-07 Chinese
107年11月營業收入
Interim / Quarterly Report Classification · 95% confidence The document is a revenue summary report for a specific month (November of year 107 in the Taiwanese calendar, which corresponds to 2018) provided by a listed company. It contains detailed financial data on net operating revenue, comparisons with the previous year, and explanations for revenue changes. The content is concise and focused on financial figures for a short period, indicating it is a periodic financial report rather than an announcement or a presentation. The presence of actual financial data and analysis for a specific month and cumulative year-to-date figures aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not an announcement of a report, nor is it a full annual report or earnings release summary. Therefore, the best classification is Interim / Quarterly Report (IR). Q4 2018
2018-12-07 Chinese
澄清媒體報導
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (科妍生物科技股份有限公司) clarifying media reports about its business activities and contracts. It explicitly states it is a clarification to ensure investor rights and mentions that actual sales numbers will be announced later according to regulations. The document is only 992 characters long and does not contain any financial statements, detailed financial data, or comprehensive report content. It is a regulatory announcement clarifying facts and correcting media speculation, typical of a Regulatory Filing (RNS).
2018-11-09 Chinese
107年第3季財務報告書 — 201804_1786_AI3.pdf
Annual Report Classification · 95% confidence The document is a detailed financial report including individual financial statements, auditor's report, accounting policies, notes, and detailed financial data for the fiscal years 2017 and 2018 (民國一〇七年度及一〇六年度). It contains an auditor's opinion from Ernst & Young, detailed balance sheets, income statements, cash flow statements, and notes on accounting policies and key audit matters. The presence of a full audit report integrated with the financial statements and notes indicates this is a comprehensive annual financial report. The document is not a brief announcement or a certification letter but a full financial report with substantive financial data and analysis. Therefore, it fits the definition of an Annual Report (10-K). FY 2018
2018-11-08 Chinese
107年第3季財務報告書 — 201804_1786_AI1.pdf
Annual Report Classification · 100% confidence The document is titled as a consolidated financial report and auditor's report for the fiscal years 107 and 106 (Taiwanese calendar years corresponding to 2018 and 2017). It includes detailed consolidated financial statements such as balance sheets, income statements, statements of changes in equity, cash flow statements, and notes to the financial statements. There is also a detailed auditor's report from Ernst & Young, including audit opinions, key audit matters, and audit scope. The document contains substantive financial data and analysis, not just an announcement or certification. The presence of the full financial statements and the auditor's report indicates this is a full Annual Report type filing, specifically a 10-K equivalent in Taiwan's regulatory context. FY 2018
2018-11-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.